Global Epilepsy Drug Market Expected To Reach XX Million By 2025

2018-05-15 11:38:49

According to a new report published by Reports Monitor titled, Global Epilepsy Drug Market, Growth Opportunities, Innovations and Forecast, 2018-2025,” the global Epilepsy Drug Market was valued at XX million in 2018, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2018 to 2025.


Epilepsy is a chronic brain disorder which leads to sudden, recurrent and uncontrolled electric disturbance in the brain. It is one of the most common neurological disorders worldwide, which people of all ages are facing. Majority of the epileptic cases are idiopathic, with no identifiable cause. At present, only symptomatic treatment through medication, surgery and implantable devices, is available, but there is no cure for epilepsy. This highlights the untapped market need for better therapeutics which would provide lucrative growth opportunities to industry players.


More Insightful Information | Request a Sample Copy @ http://bit.ly/2wIGiCF 


Rising cases of neurological disorders, higher incidence of birth related injuries, increase in road traffic injuries, growth in disease awareness and rising patient base in developing countries, are the prominent factors driving the global epilepsy drug market. Moreover, growing R&D investment and launch of extended-release formulations are further expected to propel the market growth. However, high cost of apparent drugs and low availability of Epilepsy drugs in low and middle income countries, are likely to restrict the market growth.


The global epilepsy drug market is segmented on the basis of drug type.  On the basis of drug type, the market is diversified into marketed drugs and pipeline drugs. The market, on the basis of marketed drugs is further divided as first generation drugs which includes Phenytoin, Carbamazepine, Oxycarbazepine, second generation drugs includes  Levetiracetam, Lamotrigine, Topiramate and third generation drugs includes  Lacosamide, Perampanel, Eslicarbazepine Acetate.


The global epilepsy drug market is studied across regions North America, Europe, Asia Pacific and LAMEA (Latin America, Middle East and Africa).
North America prevail the global market for epilepsy treatment increasing due to dominance of epilepsy cases in the region. Moreover, increased awareness about the neurological disorders and improved healthcare facilities are driving the market for epilepsy drug in North America. The market for epilepsy therapeutics in Asia is expected to have high growth rate, followed by Europe in forecasted years. China and India might expect a fast growth epilepsy therapeutics markets in the Asia. This is due to the large population and increasing number of epilepsy cases in these countries. Some of the key driving factors of the epilepsy drug market in developing countries are increasing awareness for different neurological disorders and improved healthcare facilities in these regions.


Key players: 
The major players in the market are GW Pharmaceuticals, Zogenix, UCB, Upsher-Smith Laboratories, Neurelis, Lundbeck, Sanofi, Pfizer, SK Biopharmaceuticals, Supernus Pharmaceuticals, Daiichi-Sankyo.


About Garner Insights:

We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.


Contact Us:

Kevin Thomas

Direct:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases